



Afuresertib HCl (GSK-2110183)

Catalog_no :	ADMC0751
Category :	抑制剂与激动剂
Size :	10mg/50mg/100mg
Specificity :	Target: PKA . Fields: Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM
Dilution :	Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1 α), 4 nM (PKG1 β)[1]
Purification :	>98%
Concentration :	靶点 : PKA;IC50 : Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1 α), 4 nM (PKG1 β)[1]
Storage_stability :	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Other_name :	Afuresertib , GSK 2110183 , GSK2110183
Molecular Weight :	463.78
Notes :	Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). Ki: 0.08 nM (AKT1), 2 nM (AKT2), 2.6 nM (AKT3)[1] IC50: 0.2 nM (AKT1E17K), 1.3 nM (PKA), 0.9 nM (PKG1 α),

Product Images

